EUVIMEDEUVIMED entdecken
Open Access

Predicting Treatment Failure With Sodium-Glucose Cotransporter-2 Inhibitors in People With Type 2 Diabetes: Novel Artificial Intelligence and Machine Learning Approach

Doyoung Kwak, Xi Tan, Yuanjie Liang, Caroline Swift, Chalak Muhammad, Xu Shi

JMIR Diabetes · 20.05.2026 · 11 · e85372-e85372

DOI: 10.2196/85372 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JMIR Diabetes, online erschienen am 20.05.2026. Verfasst von Doyoung Kwak und 5 weiteren Autor:innen. Beteiligte Einrichtung: Texas A&M University, College Station, TX, United States. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The rate of treatment failure with sodium-glucose cotransporter-2 inhibitors (SGLT2i) is high among individuals with type 2 diabetes (T2D). Accurately predicting SGLT2i treatment failure is important for improving the clinical management of T2D.

Objective

The study aimed to use machine learning (ML) models to identify factors predicting treatment failure with SGLT2i in T2D and to evaluate model performance.

Methods

This retrospective observational cohort study included adults with T2D treated with SGLT2i (2016-2024). The primary outcome was overall treatment failure with SGLT2i during follow-up (≥180 days after SGLT2i initiation). The secondary outcome was subtypes of treatment failure with SGLT2i (treatment discontinuation, failure with action, and inertial failure) or nonfailure, which was defined as not meeting the definition for one of the failure subtypes. Variables potentially associated with treatment failure were assessed during the year before SGLT2i treatment initiation (analysis 1) and the year before SGLT2i treatment failure (analysis 2). Using these variables, ML models—logistic regression (LR), multilayer perceptron (MLP), extreme gradient boosting (XGBoost), and Transformer—were used to identify significant predictors of the outcomes. Model performance metrics (accuracy, area under the curve, precision, recall, and F 1 -score) were calculated. Using Shapley Additive Explanations methodology, key features were identified based on their impact on model predictions. LR and Transformer models using key features were further evaluated for their potential to support the development of a risk score for predicting treatment failure with SGLT2i.

Results

Among all individuals in the study (N=62,222), 71% (n=44,156) had treatment failure with SGLT2i. Across subtypes, failure with action (n=23,839, 38.3%) was more common than treatment discontinuation (n=16,449, 26.4%) and inertial failure (n=3868, 6.2%). Model performance was moderate in both analyses. In analysis 1, the accuracy ranged from 0.72 to 0.73 for predicting overall treatment failure and from 0.56 to 0.57 for predicting the subtype of treatment failure. In analysis 2, the accuracy ranged from 0.74 to 0.75 for predicting overall treatment failure and from 0.61 to 0.63 for predicting the subtype of treatment failure. XGBoost, MLP, and Transformer models showed small improvements compared with LR. Using the top 9 key features identified from the Shapley Additive Explanations analysis, the Transformer model performed similarly in accuracy and area under the curve to its counterpart using the full feature set.

Conclusions

Performance across the LR, MLP, XGBoost, and Transformer models was moderate. The advanced ML models performed slightly better than LR. Overall, the results suggest that further model advancements and increased data availability are needed to better predict treatment failure with SGLT2i. The LR coefficients from the key features model may inform the development of a risk score to predict SGLT2i treatment failure. Accurate prediction could inform individualized treatment planning for individuals with T2D.

Schlagwörter

Stichwörter der Autor:innen

SGLT2iartificial intelligencemachine learningsodium-glucose cotransporter-2 inhibitorstreatment failuretype 2 diabetes

Autor:innen und Institutionen

  • Texas A&M University, College Station, TX, United States.
  • Novo Nordisk Inc, 800 Scudders Mill Road, Plainsboro, NJ, 08536, United States.
  • University of Michigan, Ann Arbor, MI, United States.

Zitieren

APA

Kwak, D., Tan, X., Liang, Y., Swift, C., Muhammad, C., & Shi, X. (2026). Predicting Treatment Failure With Sodium-Glucose Cotransporter-2 Inhibitors in People With Type 2 Diabetes: Novel Artificial Intelligence and Machine Learning Approach. JMIR Diabetes, 11, e85372-e85372. https://doi.org/10.2196/85372

Vancouver

Kwak D, Tan X, Liang Y, Swift C, Muhammad C, Shi X. Predicting Treatment Failure With Sodium-Glucose Cotransporter-2 Inhibitors in People With Type 2 Diabetes: Novel Artificial Intelligence and Machine Learning Approach. JMIR Diabetes. 2026;11:e85372-e85372. doi:10.2196/85372

BibTeX
@article{Kwak2026,
  author = {Kwak, Doyoung and Tan, Xi and Liang, Yuanjie and Swift, Caroline and Muhammad, Chalak and Shi, Xu},
  title = {Predicting Treatment Failure With Sodium-Glucose Cotransporter-2 Inhibitors in People With Type 2 Diabetes: Novel Artificial Intelligence and Machine Learning Approach},
  journal = {JMIR Diabetes},
  year = {2026},
  volume = {11},
  pages = {e85372--e85372},
  doi = {10.2196/85372}
}
Kostenlos starten →